Nicole Lemerond

Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

Center for Global Health Innovation, Inc. is a member of Georgia Bio, a non-profit life sciences association in Georgia. The non-profit company is based in Atlanta, GA. Georgia Bio works with various organizations to shape public policy, improve access to innovative technologies, and grow Georgia's life sciences economy. The CEO of the company is Maria Thacker-Goethe.

The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY.

enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

Pharm-Olam International started operations in 1994 with the premise of delivering cost effective, quick-to-market clinical services in the emerging markets of Central and Eastern Europe. Since then, POI has expanded its services to more than 40 countries, including: North America, Western Europe, Central & Eastern Europe, Latin America, India, and South Africa. Today, POI has one of the largest global footprints of any CRO. They are committed to establishing and maintaining the industry's strongest multi-national presence. Its monitors have the most extensive knowledge of local and regional customs and sites across a broad range of therapeutic areas. POI has an entirely different model than other CROs- they call it global decentralization. The success of this model has been proven time and again.

DynPort Vaccine Co. LLC develops vaccines, biologic products and small molecule anti-infectives. It provides its products and services to the defense and military sectors in the United States. The company was founded in 1997 by Zsolt Pál Harsányi and is headquartered in Reston, VA.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ.

Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA.

Ladenburg Thalmann & Co., Inc. (Broker) is the broker/dealer division of Ladenburg Thalmann & Co., Inc., ultimately held by Advisor Group Holdings, Inc. Headquartered in New York City, the firm was founded in 1876 and offers a full suite of capital markets products and services, including proprietary equity research and a fixed-income trading desk. For institutional asset management clients, the firm provides liquidity, execution, high-quality idea-generating research, and access to corporate management teams. Their institutional coverage includes relationships with over asset management companies all over the world. To corporate clients, they bring access to investor capital, broad distribution capabilities and financial markets advisory. Ladenburg Thalmann is a leader in financing growing middle-market public companies across various industry verticals, including Healthcare & Life Sciences, Yield-Oriented Securities (BDCs, REITs, MLPs), Energy, Power & Infrastructure, and Telecom, Media & Technology.

UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients.

Part of Kintara Therapeutics, Inc., Del Mar Pharmaceuticals (BC) Ltd. provides drug development services. The private company is based in Vancouver, Canada. The Canadian company was founded by William James Garner, Jeffrey A. Bacha, Dennis M. Brown. Jeffrey A. Bacha has been the CEO since incorporation. Del Mar Pharmaceuticals (BC was acquired by Kintara Therapeutics, Inc. on January 25, 2013 for $0.65 million.